# Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)

> **NCT05253118** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Seoul National University Hospital** · enrollment: 28 (estimated)

## Conditions studied

- DLBCL

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT05253118
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-18
- **Primary completion:** 2026-12-28
- **Final completion:** 2026-12-28
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-04-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05253118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05253118, "Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05253118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*